Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

C. Pasquini, Marcelo; Hu, Zhen‐Huan; J. Curran, Kevin; W. Laetsch, Theodore; L. Locke, Frederick; H. Rouce, Rayne; A. Pulsipher, Michael; L. Phillips, Christine; K. Keating, Amy; J. Frigault, Matthew; Salzberg, Dana; Jaglowski, Samantha; Sasine, Joshua; Rosenthal, Joseph; Ghosh, Monalisa; J. Landsburg, Daniel; Margossian, Steven; L. Martin, Paul; Kamdar, Manali; Hematti, Peiman; Nikiforow, Sarah; J. Turtle, Cameron; Perales, Miguel‐Angel; Steinert, Patricia; M. Horowitz, Mary; Moskop, Amy; Pacaud, Lida; Yi, Lan; Chawla, Raghav; Bleickardt, Eric; A. Grupp, Stephan

doi:10.1182/bloodadvances.2020003092

Public

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Published in Blood Advances • Nov 4, 2020

Authors:

Marcelo C. Pasquini

Zhen‐Huan Hu

Kevin J. Curran

Abstract

Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world ...

Subject

Medicine

Cytokine release syndrome

Lymphoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!